Journals / İnönü Üniversitesi Tıp Fakültesi Dergisi / 2004 / Cilt: 11 - Sayı: 3

Hipofiz makroadenomu olan 25 hastanın retrospektif olarak değerlendirilmesi

Retrospective analyses of 25 patients with pituitary macroadenomas

Pages
135–141
Publication Date
2022-10-17
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Conclusion: Despite new treatment modalities in functioning adenomas promise expectations, pituitary macroadenomas seem to sustain as a dilemma especially for the endocrinologic dysfunctions in regards of tumor mass effect or operation sequels.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Aim: The aim of this study is to retrospectively evaluate the 25 patients (15 female, 10 male, mean age 43.24 ± 15.44 years) with pituitary macroadenomas; 12 clinically non-functioning tumors (CNFTs), 6 prolactinomas, 5 acromegalies, and 2 craniopharingiomas attempted to our Neurosurgery and Endocrinology Clinics.
📊
Key Findings & Data:Results: Male dominancy was defined in CNFTs (58.3%), but in acromegalies (80%), and prolactinomas (66.6%) most of the patients were female.
💡
Conclusion & Impact:Conclusion: Despite new treatment modalities in functioning adenomas promise expectations, pituitary macroadenomas seem to sustain as a dilemma especially for the endocrinologic dysfunctions in regards of tumor mass effect or operation sequels.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Aim: The aim of this study is to retrospectively evaluate the 25 patients (15 female, 10 male, mean age 43.24 ± 15.44 years) with pituitary macroadenomas; 12 clinically non-functioning tumors (CNFTs), 6 prolactinomas, 5 acromegalies, and 2 craniopharingiomas attempted to our Neurosurgery and Endocrinology Clinics. Methods: The patients were evaluated demographically and endocrinologically with the nature of the tumor and operation modalities. Results: Male dominancy was defined in CNFTs (58.3%), but in acromegalies (80%), and prolactinomas (66.6%) most of the patients were female. Both of the craniopharingiomas were women as well. Headache was the predominant (52%) complaint for all the cases, visual disturbances (36%) and hypogonadal symptoms (16%) were the others. Hypogonadotropic hypogonadism and hypopituitarism were the most frequent endocrinologic abnormalities at admission. Eighteen of the patients were operated. In 10 (40%) of them transsphenoidal surgery, and in 8 (32%) transcranial surgery was performed. The recurrence rate was 22.2%. Hypopituitarism was increased up to 50% (n=9) from 28%, and sustained diabetes insipidus from 4% to 27.8% (n=5) postoperatively. Conclusion: Despite new treatment modalities in functioning adenomas promise expectations, pituitary macroadenomas seem to sustain as a dilemma especially for the endocrinologic dysfunctions in regards of tumor mass effect or operation sequels.

Özet

Amaç: Bu çalışmanın amacı, 2000-2004 yılları arasında Nöroşirurji ve Endokrinoloji Kliniklerimizde tedavi edilen hipofizer makroadenomlu 25 hastanın (15 kadın, 10 erkek, yaş ortalaması 43.24 ± 15.44 yıl) retrospektif olarak incelenmesidir. Yöntem: Hastalar demografik ve endokrinolojik bulgulara, tümörün çapı, yayılımı ve operasyon şekline göre değerlendirilmiştir. Bulgular: Olguların 12'si klinik olarak non-fonksiyone adenom (CNFT), 6'sı prolaktinoma, 5'i akromegali ve 2'si kranyofarinjiomadır. CNFT'lü vakalarda erkekler (%58.3), akromegali (%80) ve prolaktinomalarda (%66.6) ise kadınlar çoğunluktaydı. Kranyofarinjiomalı iki olgu da kadındı. Baş ağrısı (%52) görme bozuklukları (%36) and hipogonadal semptomlar (%16) başvuru anında belirtilen en sık şikayetlerdi. Hipogonadotropik hipogonadizm ve hipopitüitarizm tedavi öncesi tespit edilen en sık endokrinolojik bozukluklardı. Hastaların 18’i tümör özelliğine göre transsfenoidal (n=10, %40) yada transkranyal yoldan (n=8, %32) opere edildi. Nüks oranı %22.2 bulundu. Operasyonlardan sonra hipopitüitarizmin %28'den %50'ye (n=9), ve kalıcı diabetes insipidusun %4'ten %27.8'e (n=5) yükseldiği görülürken, vizyon bozukluklarının % 48'den %20'ye, oftalmopleji oranının ise %20'den %4'e düştüğü görüldü. Sonuç: Her ne kadar hipofiz adenomlarında yeni tedavi yaklaşımları umut vaat ediyorsa da, makroadenomlar gerek kitle etkileri gerekse operasyona bağlı nedenlerle endokrinolojik ve cerrahi açıdan hala ciddi bir sorun olarak görünmektedir.

🔖

Cite This Article

KESKİN, L., TARIM, Ö., ÇIKIM, A., ÇAKIR, C. Ö., ÇIKIM, K., ATEŞ, Ö. (2022). Hipofiz makroadenomu olan 25 hastanın retrospektif olarak değerlendirilmesi. İnönü Üniversitesi Tıp Fakültesi Dergisi, Cilt: 11 - Sayı: 3, 135–141. https://ajindex.com/articles/548845

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (9)

  1. Annegers JF, Coulam CB, Laws ER. Pituitary tumors: epidemiology. In: Givens JR, ed. Hormone-secreting pituitary tumors. Chicago: Year Book Medical Publishers 1982: 393- 403 2. Snyder PJ. Gonadotroph and other clinically non-functioning pituitary adenomas. Cancer Treat Res 1997
  2. 72 3. Drange MR, Fram NR, Herman-Bonert V, Melmed S. Pituitary tumor registry: A novel clinical resource. JCEM 1999
  3. 175 4. Kovacs K, Horvath E. Tumors of pituitary gland. In: Hartman WH, ed. Atlas tumor of pathology, 2nd series, Fascicle XXI. Washington: Armed Forces Institute of Pathology, 1986:1 5. Horvath E, Kovacs K. The adenohypophysis. In Kovacs K, Asa L, eds. Functional endocrine pathology. Boston: Blackwell Science, 1998:247 6. Ambrosi B, Faglia G. Epidemiology of pituitary tumors. In:Faglia G, Beck-Peccoz P, Ambrosi B, Travaglini P, Spada A, eds. Pituitary adenomas:new trends in basic and clinical research. Amsterdam: Excerpta Medica, 1991:159 7. Teramato A, Hirakawa K, Sanno N, Osamura Y. Incidental pituitary lesions in 1000 unselected autopsy specimens. Radiology 1994
  4. 161 8. Hall WA, Luciano MG, Doppman LJ, et al. Pituitary magnetic resonance imaging in normal human volunteers: occult adenomas in the general population. Ann Intern Med 1994
  5. 817 9. Thapar K, Kovacs K. Tumors of the sellar region. In:Bigner DD, McLendon RE, Bruner JM, eds. Russel and Rubinstein’s pathology of tumors of the nervous system, 6th ed. Baltimore: Williams & Wilkins 1998:561 10. Kovacs K, Horvath E, Asa SL. Classification and pathology of pituitary tumors. In: Wilkins RH, Rengachary SS, eds. Neurosurgery. New York: Mc Graw-Hill 1985: 834-842 11. Chanson P. Pituitary tumors: overview of therapeutic options. In: Becker KL e-ds. Principles and practice of endocrinology and metabolism, 3rd ed. Philadelphia: Lippincott Williams & Wilkins 2001:24
  6. 276 12. Calle-Rodrigue RDP, Giannini C, Scheithauer BW. Prolactinomas in male and female patients: a comperative clinicopathologic study. Mayo Clin Proc 1998
  7. 1052 13. Crotty TB, Young WF, Davis DH, Shaw EG, Miller GM, Burger PC. Papillary craniopharyngioma: a clinicopathological study of 48 cases. J Neurosurg 1995
  8. 214 14. Jadresic A, Banks LM, Child DF, Diamant L, Doyle FH, Fraser TR, Joplin GF. The acromegaly syndrome relation between clinical features, growth hormone values and radiological characteristics of the pituitary tumors. Quarterly Journal of Medicine 1982
  9. 51 (202): 189-204 15. Molitch ME. Prolactinoma